Are parkinson disease patients protected from some but not all cancers?: Reply

Neurology

Volumn 71, Issue 20, 2008, Pages 1650-1651

  Inzelberg, Rivka ^a   Jankovic, Joseph ^a  

^a TX ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; COLON CARCINOMA; DOPAMINERGIC NERVE CELL; HUMAN; LETTER; MELANOMA; PARKINSON DISEASE; PRIORITY JOURNAL; GENETICS; NEOPLASM; NOTE; COLON CANCER; GALLBLADDER CANCER; LUNG CANCER; MUTATION; PANCREAS CANCER; TESTIS CANCER;

HUMANS; NEOPLASMS; PARKINSON DISEASE;

EID: 58149396977     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000339367.54460.8c     Document Type: Letter

References (8)

1. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69:1542-1550.
2. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-1622.
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
4. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008;131:1969-1978.
5. Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006;251:102-106.
6. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006;12: 1102-1108.
7. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007;18:705-711.
8. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007;22:1252-1257.